INAMRINONE LACTATE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C10H9N3O.C3H6O3
Molecular Weight	277.2759
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0
Stereo Comments	LACTATE

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.NC1=CC(=CNC1=O)C2=CC=NC=C2

InChI

InChIKey=DOSIONJFGDSKCQ-UHFFFAOYSA-N

InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C10H9N3O
Molecular Weight	187.198
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01427
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/inamrinone.html

Inamrinone (Amrinone) is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. Inamrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect. Inamrinone is used in the treatment of congestive heart failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 3A 7 Target ID: CHEMBL241 Sources: http://www.drugbank.ca/drugs/DB01427	Inhibitor 8504	16.7 µM [IC50]
Phosphodiesterase 3B 8 Target ID: CHEMBL290 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10644042	Inhibitor 8504	31.2 µM [IC50]
platelet aggregation 80 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698653	Inhibitor 8504	61.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Congestive heart failure 54 Sources: https://www.drugs.com/pro/inamrinone.html	Primary		Approved 8583	AMRINONE LACTATE Approved Use For the short-term management of congestive heart failure. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
5.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
198 ug/kg/min 1 times / day single, intravenous Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 Health Status: unhealthy Age Group: 0.208333333333333 Sex: F Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Death... Other AEs: Death (grade 5) Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
198 ug/kg/min 1 times / day single, intravenous Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 Health Status: unhealthy Age Group: 0.208333333333333 Sex: F Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Cardiac arrest... Other AEs: Cardiac arrest Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	Disc. AE: Pulmonary edema, Cardiac arrest... AEs leading to discontinuation/dose reduction: Pulmonary edema Cardiac arrest Respiratory distress syndrome Chest pain Palpitations Ventricular ectopic beats Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 Health Status: unhealthy Age Group: 53 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	Disc. AE: Diarrhea, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Diarrhea Thrombocytopenia Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
5.8 mg/kg/day 1 times / day multiple, intravenous Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) Health Status: unhealthy Age Group: 59.4 (37-81) Sex: M+F Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (18.6%) Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456
3 mg/kg 1 times / day single, intravenous Recommended Dose: 3 mg/kg, 1 times / day Route: intravenous Route: single Dose: 3 mg/kg, 1 times / day Sources: https://www.nature.com/articles/pr1984440	unhealthy, <1 Health Status: unhealthy Age Group: <1 Sex: M+F Sources: https://www.nature.com/articles/pr1984440	Sources: https://www.nature.com/articles/pr1984440

AEs

AE	Significance	Dose	Population
Death	grade 5	198 ug/kg/min 1 times / day single, intravenous Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 Health Status: unhealthy Age Group: 0.208333333333333 Sex: F Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Cardiac arrest		198 ug/kg/min 1 times / day single, intravenous Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 Health Status: unhealthy Age Group: 0.208333333333333 Sex: F Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Cardiac arrest	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Chest pain	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Palpitations	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Pulmonary edema	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Respiratory distress syndrome	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Ventricular ectopic beats	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 Health Status: unhealthy Age Group: 49 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Diarrhea	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 Health Status: unhealthy Age Group: 53 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 Health Status: unhealthy Age Group: 53 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	18.6% Disc. AE	5.8 mg/kg/day 1 times / day multiple, intravenous Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) Health Status: unhealthy Age Group: 59.4 (37-81) Sex: M+F Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00216	http://www.3bsc.com/index/pro_info.php?id=20428
3B Scientific (Wuhan) Corp	3B2-0633	http://www.3bsc.com/index/pro_info.php?id=19989
Acadechem	ACDS-033154	http://www.acadechemical.com/product/107853
Achemo Scientific Limited	AC-16677	http://www.achemo.com/search/?Keyword= 60719-84-8
Achemtek	0104-017105	http://www.achemtek.com/60719-84-8
AEchem Scientific Corp., USA	AE044729	http://www.aechemsc.com/info_products/AE044729.php
AHH Chemical co.,ltd	API-1603	http://www.ahhchemical.com/product/API-1603.html
AHH Chemical co.,ltd	MT-00030	http://www.ahhchemical.com/product/MT-00030.html
AK Scientific, Inc. (AKSCI)	868269	http://www.aksci.com/item_detail.php?cat=868269
Alfa Chemistry	AP60719848	https://reagents.alfa-chemistry.com/product/amrinone-cas-60719-84-8-13957.html
Alichem	22004023	http://www.alichem.com/en/products/216151-27-8.html
Allbio Pharm Co., Ltd	AD03248	http://www.allbiopharm.com/product/n/AD03248
Ambinter	Amb18649580	http://www.ambinter.com/reference/18649580
Angel Pharmatech	AG337888	http://www.angelpharmatech.com/60719-84-8.html
Angene	AGN-PC-0JK6MN	http://www.angenechemical.com/productshow/AGN-PC-0JK6MN.html
Anward	ANW-56874	http://www.anward.com/pro_result/43325
Ark Pharm	AK-99994	http://www.arkpharminc.com/products/60719-84-8.html
Aurora Fine Chemicals LLC	A02.558.326	http://online.aurorafinechemicals.com/info?ID=A02.558.326
Aurum Pharmatech LLC	M-2461	http://www.Aurumpharmatech.com/Product/ProductDetails/M_2461
Avantor Inc	101094-302	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-302
Avantor Inc	101096-786	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-786
BioChemPartner	BCP12764	http://www.biochempartner.com/60719-84-8-BCP12764
BioSynth	W-105234	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/W-105234.html
BLD Pharm	BD12830	http://www.bldpharm.com/products/60719-84-8.html
Chem Scene	CS-0013064	http://www.chemscene.com/60719-84-8.html
ChemMol	30101988	http://www.chemmol.com/chemmol/30101988.html
ChemMol	49424520	http://www.chemmol.com/chemmol/49424520.html
Chemspace	CSSB00000063426	https://chem-space.com/CSSB00000063426
Clearsynth	CS-T-03714	https://www.clearsynth.com/en/CST03714.html
Combi-Blocks	QA-1160	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1160
CSNpharm	CSN10951	https://www.csnpharm.com/products/amrinone.html
DC Chemicals	DC8957	http://www.dcchemicals.com/product_show-Amrinone.html
eNovation Chemicals	D673798	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673798
eNovation Chemicals	D765978	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765978
eNovation Chemicals	D961064	https://www.enovationchem.com/ProductDetails.asp?ProductID=D961064
Finetech	FT-0601595	http://www.finetechnology-ind.com/prod/detail/pub/60719-84-8.html
Glentham Life Sciences	GP7331	http://www.glentham.com/products/product/GP7331/
Hairui	HR132658	http://www.hairuichem.com/en/product/60719-84-8.html
Lab Network	LN00194482	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194482
mcule	MCULE-2781267039	https://mcule.com/MCULE-2781267039/
MedChem Express	HY-B1294	https://www.medchemexpress.com/amrinone.html
OChem	822	http://www.ocheminc.com/index.php?act=psearch&pid=719A848
Sigma-Aldrich	1034308_USP	https://www.sigmaaldrich.com/catalog/product/usp/1034308?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A4056_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4056?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017497	http://www.sinfoobiotech.com/product/1020895
Smolecule	S518817	http://www.smolecule.com/products/s518817
THE BioTek	bt-259866	https://www.thebiotek.com/product/inhibitors/bt-259866

PubMed

Title	Date	PubMed
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.	2009-12	19876734
Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009-10-07	19821445
Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009-10-07	19821421
Drug effect unveils inter-head cooperativity and strain-dependent ADP release in fast skeletal actomyosin.	2009-08-21	19520847
Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents.	2009-08	19555170
Evaluation of preoperative intra-aortic balloon pump in coronary patients with severe left ventricular dysfunction undergoing OPCAB surgery: early and mid-term outcomes.	2009-07-27	19635155
The role of phosphodiesterase 3 in endotoxin-induced acute kidney injury.	2009-06-01	19486524
Effects of propofol on responses of rat isolated renal arteriole to vasoactive agents.	2009-01-27	19540932
Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.	2009-01	18930951
Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury.	2009-01	18468627
Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin.	2009	19381349
Effect of nitric oxide/cyclic guanosine mono-phosphate pathway on gallbladder relaxant response in bile duct-ligated guinea pigs.	2009	19246926
Tadalafil in the treatment of erectile dysfunction.	2008-12	19337438
The base exchange reaction of NAD+ glycohydrolase: identification of novel heterocyclic alternative substrates.	2008-11-15	18835239
Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety.	2008-05-27	18505576
Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.	2008-04	18506213
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.	2008-03	18387066
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.	2008-01	18058085
Peripartum cardiomyopathy: review of the literature.	2007-10-31	17963329
[Protection of amrinone against lung injury induced by ischemia/reperfusion in rats].	2007-06	17582263
Cirrhotic cardiomyopathy.	2007-03-27	17389039
Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method.	2007-02-23	17207464
[Current approaches to intraoperative diagnosis and treatment of low cardiac output during cardiosurgical operations].	2006-12-23	17184052
Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.	2006-12-06	17146843
Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.	2006-11-21	17118183
Acute heart failure: inotropic agents and their clinical uses.	2006-11	17059376
Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.	2006-10-01	16990629
Proper use of phosphodiesterase inhibitors according to the situations.	2006-09	17037008
Alkaline Phosphatases : Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes.	2006-06	18404473
Effect of combining phosphodiesterase III inhibitors with St Thomas Hospital's solution used as transplantation preservative solution in isolated rat hearts.	2006-06	16797275
A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.	2006-06	16717301
Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.	2006-05	16369769
The effect of amrinone on liver regeneration in experimental hepatic resection model.	2006-01	16154150
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.	2006	17096864
Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers.	2006	16732893
In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats.	2006	16319452
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.	2005-12-28	16325808
Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.	2005-11	16236146
Effects of inotropic drugs on mechanical function and oxygen balance in postischemic canine myocardium: comparison of dobutamine, epinephrine, amrinone, and calcium chloride.	2005-10	16224144
Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries.	2005-10	16192501
Effect of amrinone on mucosal permeability in experimental intestinal ischaemia/reperfusion injury.	2005-07	15972057
A sensitive and specific high performance liquid chromatographic assay for milrinone in rat and human plasma using a commercially available internal standard and low sample volume.	2005-06-24	16124923
The impact of slow rewarming on inotropy, tissue metabolism, and "after drop" of body temperature in pediatric patients.	2005-06	16117455
Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.	2005-06	15987381
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.	2005-05-09	15910807
Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine.	2005-04	15892406
SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure.	2005-01	15644593
Meta-analysis of hemodynamic optimization: relationship to methodological quality.	2005	16356226
Congenital junctional ectopic tachycardia: presentation and outcome.	2003-07-01	16943912
Amrinone for refractory cardiogenic shock following chloroquine poisoning.	1991	1774400

Patents

Sample Use Guides

In Vivo Use Guide

Congestive heart failure IV Initially, 0.75 mg/kg as a slow (over 2–3 minutes) direct injection; if warranted, may administer a supplemental direct IV dose of 0.75 mg/kg 30 minutes after the initial dose.1 60 Direct IV injection is followed by an IV infusion of 5–10 mcg/kg per minute. Duration of therapy determined by clinical response and tolerance to adverse effects.

Route of Administration: Intravenous

In Vitro Use Guide

Inamrinone inhibited human platelet aggregation at 10,800 s(-1) in a dose-dependent manner with the IC(50) value of 61 +/- 8 uM (mean +/- S.D.), Inamrinone significantly inhibited platelet aggregation at 1200 s(-1) only at highest concentration tested (100 uM)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:56 GMT 2025`
Record UNII	I229274Y5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INAMRINONE LACTATE

Common Name

English

AMRINONE LACTATE

Preferred Name

English

Amrinone lactate [WHO-DD]

Common Name

English

INOCOR

Brand Name

English

INAMRINONE LACTATE [ORANGE BOOK]

Common Name

English

PROPANOIC ACID, 3-HYDROXY-, COMPD. WITH 5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE

Common Name

English

INAMRINONE LACTATE [VANDF]

Common Name

English

5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE LACTATE

Systematic Name

English

AMRINONE LACTATE [MART.]

Common Name

English

AMRINONE LACTATE [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744